Myelofibrosis

Sue’s IncyteCARES Story


Hear Sue’s IncyteCARES Story

Hear Sue share how IncyteCARES—a patient support program for eligible adults taking Jakafi® (ruxolitinib)—connected her with information regarding coverage and educational support to help her throughout her journey with Jakafi.

Video Transcript

Sue: I'm Sue. I'm a mother of three boys. I've been married for 26 years and I run a home daycare.

Onscreen text: Sue was first prescribed Jakafi® (ruxolitinib) in 2012.

Sue: My hematologist told me about this new drug called Jakafi…

Sue: So when I started Jakafi I received a lot of information about it. I heard about this program called IncyteCARES that helps with copays on Facebook so I called the number. IncyteCARES sent out packages and all kinds of materials…

Narrator: IncyteCARES is the one-stop destination specifically tailored for people prescribed Jakafi® (ruxolitinib).

Onscreen text: The one-stop destination specifically tailored for people prescribed Jakafi® (ruxolitinib)

Sue: So at first I really didn’t need their help, but then my copay changed drastically. So I contacted them and got copay assistance to a very manageable level and then I learned about the other programs that they offer.

Onscreen text:

Support Services

  • Medication initiation
  • Educational resources
  • Coverage clarity
  • Financial Assistance Options
  • Copays as low as $0*

*Terms and conditions apply.

Narrator: Jakafi patients, like Sue, come to rely on IncyteCARES team members to help get them started on Jakafi, provide access to educational support resources, and explain coverage and financial assistance options that may even include zero-dollar copays for eligible patients.

Onscreen text: Patient support and resources to help manage daily life

Narrator: From their first prescription, IncyteCARES supports patients with both a welcome kit and resources for managing daily life.

Sue: I received all kinds of information packets in the mail. They’re available online or, you know, they-they mailed the packets to me. I still get them. They offer emotional support. You can contact nurses directly.

Onscreen text:

Resources

  • HCP conversation guides
  • Live team-member access
  • Symptom/medicine tracking tools
  • Transportation provider links

Narrator: In fact, IncyteCARES offers a range of resources designed to help support and inform conversations with Healthcare Professionals, to help patients maintain a positive outlook, and to provide symptom tracking and daily medicine monitoring, as well as connections to transportation providers, and more.

Sue: IncyteCARES just provides you knowledge and support. With a rare disease it’s, it’s nice to have someplace to go to, to talk and learn.

Onscreen text and narrator: IncyteCARES is an assistance program for eligible patients and their caregivers that can provide support when starting Jakafi® (ruxolitinib) and throughout the treatment journey.

Narrator: Connect with IncyteCARES today!
Visit IncyteCARES.com or call 1-855-452-5234.

Onscreen text: Connect with IncyteCARES today!
Visit: IncyteCARES.com or call:1-855-452-5234, Monday through Friday, 8 am–8 pm ET

Onscreen text: This video is sponsored by Incyte Corporation.

Jakafi and the Jakafi logo are registered trademarks of Incyte.
© 2020, Incyte Corporation. MAT-INC-00518  09/20

connect-patient

Connect With
a Patient
Like Dan

Connect With a
Patient Like Dan

Register for the Incyte Mentor Program and connect with another patient taking Jakafi.

Email Address

Continue Registering

Expand Collapse

INDICATIONS AND USAGE

INDICATIONS AND USAGE

Jakafi is a prescription medicine used to treat adults with polycythemia vera who have already taken a medicine called hydroxyurea and it did not work well enough or they could not tolerate it.

Jakafi is used to treat adults with certain types of myelofibrosis.

Jakafi is also used to treat adults and children 12 years of age and older with acute graft-versus-host disease (GVHD) who have taken corticosteroids and they did not work well enough.

Important Safety Information

Jakafi can cause serious side effects, including:

Low blood counts: Jakafi® (ruxolitinib) may cause your platelet, red blood cell, or white blood cell counts to be lowered. If you develop bleeding, stop taking Jakafi and call your healthcare provider. Your healthcare provider will perform blood tests to check your blood counts before you start Jakafi and regularly during your treatment. Your healthcare provider may change your dose of Jakafi or stop your treatment based on the results of your blood tests. Tell your healthcare provider right away if you develop or have worsening symptoms such as unusual bleeding, bruising, tiredness, shortness of breath, or a fever.

Infection: You may be at risk for developing a serious infection during treatment with Jakafi. Tell your healthcare provider if you develop any of the following symptoms of infection: chills, nausea, vomiting, aches, weakness, fever, painful skin rash or blisters.

Skin cancers: Some people who take Jakafi have developed certain types of non-melanoma skin cancers. Tell your healthcare provider if you develop any new or changing skin lesions.

Increases in cholesterol: You may have changes in your blood cholesterol levels. Your healthcare provider will do blood tests to check your cholesterol levels during your treatment with Jakafi.

The most common side effects of Jakafi include: for certain types of MF and PV – low platelet or red blood cell counts, bruising, dizziness, headache, and diarrhea; and for acute GVHD – low platelet, red or white blood cell counts, infections, and fluid retention.

These are not all the possible side effects of Jakafi. Ask your pharmacist or healthcare provider for more information. Tell your healthcare provider about any side effect that bothers you or that does not go away.

Before taking Jakafi, tell your healthcare provider about: all the medications, vitamins, and herbal supplements you are taking and all your medical conditions, including if you have an infection, have or had tuberculosis (TB) or have been in close contact with someone who has TB, have or had hepatitis B, have or had liver or kidney problems, are on dialysis, have high cholesterol or triglycerides, had skin cancer, or have any other medical condition. Take Jakafi exactly as your healthcare provider tells you. Do not change your dose or stop taking Jakafi without first talking to your healthcare provider.

Women should not take Jakafi while pregnant or planning to become pregnant. Do not breastfeed during treatment with Jakafi and for 2 weeks after the final dose.

Please see the Full Prescribing Information, which includes a more complete discussion of the risks associated with Jakafi.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

You may also report side effects to Incyte Medical Information at 1-855-463-3463.